---
schema_version: "secwatch.filing_event.v1"
accession: "0001615219-25-000107"
form_type: "8-K"
ticker: "DCOY"
cik: "0001615219"
company_name: "Decoy Therapeutics Inc."
filed_at: "2025-08-18T23:59:59+00:00"
generated_at: "2026-05-17T11:56:03.734139+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Salarius Pharma CEO David J. Arthur resigns; CFO Mark J. Rosenblum named acting CEO

## Summary
- David J. Arthur resigned as CEO effective Aug 17, 2025; not due to any disagreement with the company.
- Mark J. Rosenblum appointed acting CEO, continuing as EVP and CFO; no new employment agreement.
- Consulting agreement with Arthur terminated immediately upon resignation.
- Rosenblum has served as EVP Finance/CFO since Sep 2019; previously CFO of Advaxis, Inc.
- Company working to finalize previously announced merger with Decoy Therapeutics Inc.

## SEC filing metadata
- accession: 0001615219-25-000107
- form_type: 8-K
- ticker: DCOY
- cik: 0001615219
- company_name: Decoy Therapeutics Inc.
- filed_at: 2025-08-18T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 5.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1615219/000161521925000107/0001615219-25-000107-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1615219/000161521925000107/flks-20250817.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001615219-25-000107
- JSON: https://secwatch.observer/filing/0001615219-25-000107.json
- Plain text: https://secwatch.observer/filing/0001615219-25-000107.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.